<DOC>
	<DOCNO>NCT02968576</DOCNO>
	<brief_summary>Poor adherence tenofovir ( TDF ) emtricitabine ( FTC ) Human Immunodeficiency Virus ( HIV ) pre-exposure prophylaxis ( PrEP ) common lead cause therapeutic failure . The investigator need good way measure adherence patient PrEP . This application address need measure adherence evaluate integrate technology system , Proteus Discover , combine Truvada . The Proteus Sensor System ( PSS ) confirm Truvada take , monitor adherence recent long term dosing , provide feedback encourage adherence . The goal study determine whether use PSS Truvada vary drug concentration FTC/TDF . Participants 2 study visit randomize either start combined PSS Truvada Truvada alone . Study participants come Clinical &amp; Translational Research Center ( CTRC ) morning take assign dose blood drawn .25 , 0.5 , 1 , 2 , 4 , 6 , 10 hour medication take . Participants return CTRC blood draw 24 , 48 , 72 hour take dose first day . The second visit mimic first except participant take dose form .</brief_summary>
	<brief_title>Bioequivalence Tenofovir Emtricitabine Following Overencapsulation</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>1 . Ambulatory 1845 year old adult . 2 . Ability comply study procedures 1 . Inability give inform consent 2 . Pregnancy plan become pregnant within 3 month study completion 3 . Currently breastfeed 4 . High risk HIV1 infection ( example : sexually active HIV infect partner ; men sex men may engage condomless intercourse HIVinfected partner partner unknown status study ; male females exchange sex money , shelter , gift ; active injection drug use last 12 month ; newly diagnose sexually transmit infection last 6 month ) 5 . Positive HIV+ ELISA suspect acute HIV infection opinion clinician . ( example sign symptom acute HIV infection include combination fever , headache , fatigue , arthralgia , vomit , myalgia , diarrhea , pharyngitis , rash , night sweat , adenopathy cervical inguinal ) 6 . Positive hepatitis B virus ( HBV ) surface antigen test . 7 . Uncontrolled symptomatic bone disease history nontraumatic bone fracture 8 . Active psychiatric illness alcohol/drug abuse , opinion investigator , would interfere study requirement 9 . Creatinine clearance &lt; 60 ml/min , history serious renal disease 10 . Urine dipstick protein ≥ 2+ 11 . Total bilirubin and/or hepatic transaminase ( ALT AST ) ≥ 2.5x upper limit normal 12 . Absolute neutrophil count ≤ 1,500/mm3 , platelet count ≤ 100,000/mm3 , hemoglobin ≤ 10 g/dL . 13 . Any laboratory value uncontrolled medical condition , opinion investigator , would interfere study condition increase risk participant 14 . &gt; Grade I abnormalities screen laboratory test ( Complete Blood Count , Comprehensive Metabolic Panel , Lipase , Phosphorus ) per Division AIDS ( DAIDS ) Grading Table 15 . Contraindicated concomitant medication base upon product information , opinion investigator , would interact study medication increase risk participant : investigational agent ( within 30 day enrollment ) , aminoglycosides , ganciclovir/valganciclovir , chronic highdose acyclovir/valacyclovir ( &gt; 800mg acyclovir &gt; 500mg valacyclovir &gt; 7 day ) , cyclosporine , amphotericin B , foscarnet , cidofovir , product similar active ingredient study medication include TRUVADA® , ATRIPLA® , COMPLERA® , EMTRIVA® , VIREAD® ; drug contain lamivudine adefovir , close analog FTC tenofovir . 16 . Current participation interventional research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>